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Drugs targeting immune checkpointmole-
cules such as CTLA-4, PD-1, and PD-L1
are being heralded as a breakthrough
in oncology. However, ‘‘breakthrough’’ is
a misnomer belying several decades of
basic immunology advances and clinical
trial and error leading up to this point. It
was only after basic science uncovered
the protean pathways restraining anti-
tumor immunity that we could begin
to unravel how to subvert them. The
broad activity spectrum of PD-1 pathway
blockers against multiple cancer types
has validated this as a ‘‘common denomi-
nator’’ treatment approachanddispels the
perception that ‘‘immunogenic’’ cancers
are anomalies. We are now challenged to
understand immune resistance mecha-
nisms utilized by ‘‘non-responsive’’ tumor
types (e.g., prostate cancer) as well as
the 50% or more of individuals with
‘‘responsive’’ tumor types who do not
benefit from these drugs. Identifying
collateral pathways for co-targeting in
combination treatment regimens requires
an intellectual leap to consider unex-
pected intersections between the immune
system and genetics, epigenetics, and
metabolism. For instance, tumor muta-
tional density, a surrogate indicator of neo-
antigens available for immune recognition,
correlates with the responsiveness ofmel-
anoma to anti-CTLA-4, and lung cancer to
anti-PD-1. In the final analysis, teamwork
with cross-fertilization of ideas across
different scientific disciplines has driven
the evolution to today’s ‘‘breakthroughs’’
and will meet tomorrow’s challenges.Central Dogma for Immunotherapy
Jedd D. Wolchok and Timothy A. Chan
Memorial Sloan Kettering Cancer Center
In biology classes, we learned about the
central dogma of molecular biology—
DNAmakes RNA and RNAmakes protein.
We’ve also learned about factors that
regulate this central process, such as the
influence of epigenetics, micro-RNAs,
and mechanisms regulating post-tran-
scriptional and translational control.
Despite the fine intricacies, the central
dogma of molecular biology remains
intact—inherently elegant and graspable.
A unifying concept for cancer immu-
nology, on the other hand, has remained
elusiveuntil recently.Wenowhavediscov-
ered the existence of molecular mecha-
nisms of immune surveillance (thanks to
Bob Schreiber) and that the number and
quality of immune cells within the tumor
microenvironment has significant prog-
nostic impact in a variety of cancers. The
quantity and quality of so-called ‘‘passen-
ger’’ mutations in the tumor are also very
important in determining the likelihood
of success of immunologic checkpoint
blockade with CTLA-4 or PD-1 pathway
blocking antibodies. A putative dogma
therefore is that mutations drive baseline
immune reactivity and baseline immune
reactivity is what determines the potential
for benefit of immune potentiating thera-
pies. As in molecular biology, there are
likely to be modifiers, such as inhibitory
cells populations, hostile microenviron-
ments, and loss of antigen presenting
capacity. Yet, a unifying concept will
likely allow the field to further refine its
approaches and specifically address the
immunologic needs of individual patients.CelNot Just Another Hallmark
Ira Mellman
Genentech
After an incubation period of nearly
100 years, cancer immunotherapy has
emerged as a transformative approach
to treat a wide variety of cancers.
Although still early days, immunotherapy
provides a degree of sustained clinical
benefit rarely observed with more tradi-
tional cancer treatments. The excitement
is, therefore, being largely driven by
clinical results rather than by ‘‘break-
throughs’’ in the laboratory. There are
nevertheless two daunting challenges.
First, the field has progressed so rapidly
in the clinic that our understanding of
the underlying basic science and mecha-
nisms of action are remarkably thin.
Second, the tools we have to assess
mechanism and correlates of treatment
response (or lack thereof) remain rudi-
mentary. Meeting these challenges is crit-
ical, since only a minority of patients
as yet exhibit maximal benefit from immu-
notherapy. Importantly, clinical responses
to agents such as anti-PD-L1/PD-1 are
often clear and dramatic, thereby creating
the opportunity to discover biomarkers
and use them to understand inevitable
patient to patient variations. Exploiting
these correlates of clinical response will
provide insights into basic cancer biology
and inform immunotherapy combinations
that can be expected to result in higher
response rates and disease cures. Our
task will be to backfill the science behind
an exciting and validated therapeutic
approach, ensuring that the field can
look forward to a very exciting next
decade both in the lab and in the clinic.l 161, April 9, 2015 ª2015 Elsevier Inc. 185
New Trends in Cancer Vaccines
Karolina Palucka and Jacques Banchereau
The Jackson Laboratory for Genomic Medicine
Clinical responses to checkpoint
blockade are linked to the presence of
T cell immunity to cancer-specific muta-
tions. One way to increase the rate of
clinical responses is to use vaccination
to expand T cells specific for cancer
mutations. Several phase III clinical trials
testing different cancer vaccine candi-
dates are currently ongoing. Exogenous
vaccines utilize, for instance, dendritic
cell-based and viral vectors-based ap-
proaches to boost the immune response
in cancer patients. To be successful,
these platforms will require applying
high-throughput genomics to identify
cancer-specific mutations and candidate
peptide antigens in each patient in
order to produce personalized vaccines.
An alternative approach, endogenous
vaccination, is based on exploiting the
local release of antigens that happens
upon standard cancer therapy (chemo-
therapy or radiotherapy) or oncolytic viral
therapy. However, this strategy requires
endogenous antigen presentation to be
effective, in order to generate therapeutic
T cell immunity. Dendritic cells are often
skewed by tumors to generate pro-tumor
immunity and thus reprogramming of
their function in vivo is critical for the
success of endogenous vaccination.
Increasing the understanding of cancer
genomics, the biology of antigen pre-
sentation and T cell biology will enable
development of next-generation cancer
vaccines which, combined with check-
point blockade inhibitors, will pave the
path to curative therapies for patients
with cancer.186 Cell 161, April 9, 2015 ª2015 Elsevier IncPersonalized Immunotherapy
Steven A. Rosenberg
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Adoptive cell transfer (ACT) uses patient’s
lymphocytes to treat their autologous
cancer. When tumor infiltrating lympho-
cytes are used for ACT, they can mediate
complete, likely curative, regression
in patients with metastatic melanoma.
Lymphocytes genetically engineered to
express anti-tumor receptors can treat
patients with refractory lymphomas and
leukemias. However, the majority of
metastatic epithelial cancers are still
resistant to immunotherapy. Recent ap-
proaches using deep exome sequencing
along with high-throughput immunologic
testing opened the door to treat these
common types of cancer and to identify
the rare somatic mutations that are immu-
nogenic. ACT targeting these mutations
is the ultimate ‘‘personalized’’ cancer
treatment but is contrary to the mantra
of many pharmaceutical companies who
want ‘‘drugs in a vial’’ that can be mass
produced and distributed. Although this
approach has produced drugs that pro-
long the life of patients with solid meta-
static cancers, curative treatments are
rare and have had limited impact on
overall death rates from cancer. A highly
‘‘personalized’’ immunotherapy for com-
mon cancers may require the develop-
ment of a unique drug (autologous lym-
phocytes) for each patient. It will also
need major changes and considerable
flexibility on the part of industry. The
effectiveness of treatment should trump
simplicity of production and convenience
of administration if progress is to be
made in enabling patients with metastatic
cancer to be cured and relish a normal
lifespan..The New Immune Engineers
K. Dane Wittrup
Koch Institute for Integrative Cancer Research, MIT
What vaccine best exploits the evolu-
tionary weaknesses of a virus or a tumor’s
mutations? What is the intratumoral
exposure history of intravenously injected
antibodies? How does deregulated
signaling tip the balance from healthy
homeostasis to autoimmune disease?
Can native T cell tropism overcome
physical barriers to macromolecular drug
delivery? How does our antibody reper-
toire respond to therapy or disease?
How might innate and adaptive immuno-
therapies best be combined? How does
lymphatic transport actively regulate
adaptive immunity? Can injectable bio-
materials program an effective anti-tumor
immune response? A common thread
through these varied and timely topics is
the engagement of biological, chemical,
and materials engineers at the forefront.
At their disposal is an analytical toolkit
honed to solve problems in the petro-
chemical and materials industries, which
share the presence of complex reaction
networks and convective and diffusive
molecular transport. Powerful synthetic
capabilities have also been crafted:
binding proteins can be engineered
with effectively arbitrary specificity and
affinity, and multifunctional nanoparticles
and gels have been designed to interact
in highly specific fashions with cells and
tissues. Fearless pursuit of knowledge
and solutions across disciplinary bound-
aries characterizes this nascent discipline
of immune engineering, synergizing with
immunologists and clinicians to put
immunotherapy into practice.
